/

CANF

Can-Fite Biopharma LtdClosed

1.950.00 0.00%USD

NYSE American · as of Oct 13, 16:00 ETAfter hours 1.90 −1.94%

Open

1.97

Prev close

1.95

Day range

1.912.00

52-week range

1.9012.40

Volume

19.56K0.05×

Mkt cap

5.91M

P/E ttm

—

Fwd P/E

-2.14

EPS ttm

-13.23

Div yield

0.00%

Earnings

—

From 52w high

−84.27%

Price Chart

Yahoo Finance · delayed

CANFOct 13, 2026O 1.97H 2.00L 1.91C 1.950.00 (0.00%)Vol 19.60K

SMA 502.68
SMA 2003.36

1Y change −80.88% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CANF Can-Fite Biopharma Ltd · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.88%
1 month: −16.31%
3 months: −39.44%
6 months: −36.07%
Year to date: −51.25%
1 year: −80.88%

Valuation & ownership

Market cap: 5.91M
Enterprise value: −2.82M
P/E (ttm): —
Forward P/E: -2.14
PEG ratio: —
Price / book: 0.86
Price / sales (ttm): 14.60
EV / EBITDA: 0.29
EPS (ttm): -13.23
EPS (forward): -0.9100
Beta (5y monthly): -0.02
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 3.03M
Float: 2.14M
Short % of float: 1.84%
Short ratio (days): 0.06
Held by insiders: 0.00%
Held by institutions: 1.88%
Avg volume (3m): 373.00K
50-day average: 2.70
200-day average: 3.37
52-week change: −80.88%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 27.9
vs 50-day SMA: −27.16%
vs 200-day SMA: −42.01%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 5.25%
Realised vol (20d, ann.): 33.4%
From 52-week high: −84.27%
From 52-week low: +2.63%

ANR

Analyst Consensus

1 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

8.00

+310.26% implied

Low 8.00Median 8.00High 8.00

Recommendation trend

Now1 / 0 / 0
1m ago1 / 0 / 0

Buy / hold / sell counts

DES

About Can-Fite Biopharma Ltd

Yahoo Finance profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Sector: Healthcare
Industry: Biotechnology
Employees: 5
Headquarters: Ramat Gan, Israel
Website: canfite.com
Officers: Dr. Pnina Fishman Ph.D. Founder, Chief Scientific Officer & Executive Chairperson
Mr. Motti Farbstein CEO, CFO, Financial & Operating Officer

SEAS

Seasonality · CANF

2012–2026 · monthly returns

Strongest month Nov +6.58%Weakest month Dec −10.10%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.3	18.5	-34.7	2.9	5.0	-11.3	6.1	1.0	-30.8	-11.4			−51.2%
2025	-9.2	18.9	-15.9	-26.4	-0.9	-2.8	-36.2	-6.0	-1.6	-32.3	-16.7	-42.9	−87.7%
2024	-4.1	1.4	3.7	-6.8	14.0	9.3	23.6	-30.4	-9.5	7.0	2.3	-25.9	−25.9%
2023	-32.1	-34.5	-15.5	-24.0	48.3	19.0	-1.6	-2.6	-9.9	-23.4	15.8	-6.4	−63.9%
2022	-9.3	0.9	5.1	-25.0	1.1	-2.1	-9.8	13.3	-18.1	13.0	-3.4	-27.4	−52.7%
2021	10.7	3.6	21.1	-12.1	-0.5	5.6	-12.3	-7.0	-10.8	-8.4	-21.1	7.5	−27.5%
2020	-34.8	-41.9	4.8	38.9	18.1	-7.9	21.7	-7.5	-20.6	-2.3	9.8	-6.3	−46.1%
2019	-4.8	-3.3	-24.1	-39.8	-61.4	-6.2	0.0	-14.9	-15.9	17.5	46.3	-6.8	−82.5%
2018	60.8	-21.0	-23.4	-7.6	-3.8	-7.8	-0.8	9.4	0.8	-4.7	8.1	-5.3	−14.9%
2017	-24.8	8.9	-2.1	-1.0	-6.3	1.1	-1.1	-5.6	1.2	-7.7	-7.7	2.8	−37.8%
2016	-24.7	-4.1	32.2	1.8	1.1	-10.8	-18.0	18.1	5.6	-7.6	-9.1	8.2	−18.5%
2015	-8.0	39.8	-50.4	22.4	-15.8	-4.8	-10.5	-9.7	133.9	-19.6	5.1	-16.6	−16.6%
2014	-19.3	24.1	-16.6	-0.8	-20.1	-10.3	5.0	3.5	-15.7	-15.0	47.5	-14.6	−41.8%
2013	7.6	-10.0	4.8	-8.9	-11.0	-0.8	9.8	-2.4	21.2	12.9	8.6	-2.6	+26.8%
2012												-5.2	−5.2%

CANF

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CANF

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Can-Fite Biopharma Ltd

Seasonality · CANF

Insider Activity · CANF

Congress Trades · CANF

Investors Holding CANF

Investors Holding CANF

Congress Trades · CANF

Insider Activity · CANF

Seasonality · CANF

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Can-Fite Biopharma Ltd

Financial Snapshot

Earnings & Dividends

News